Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
87,196,691
-
Total 13F shares
-
2,150,633
-
Share change
-
+2,066,952
-
Total reported value
-
$4,086,190
-
Price per share
-
$1.90
-
Number of holders
-
49
-
Value change
-
+$4,064,925
-
Number of buys
-
47
-
Number of sells
-
2
Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock (XFOR) as of Q2 2025
As of 30 Jun 2025,
X4 Pharmaceuticals, Inc - Common Stock (XFOR) was held by
49 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,150,633 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, KINGDON CAPITAL MANAGEMENT, L.L.C., VANGUARD GROUP INC, BlackRock, Inc., GSA CAPITAL PARTNERS LLP, UBS Group AG, JANE STREET GROUP, LLC, BANK OF AMERICA CORP /DE/, OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC), and MILLENNIUM MANAGEMENT LLC.
This page lists
49
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.